Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GE HealthCare Technologies Inc. (GEHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock listed on Nasdaq under the symbol GEHC, GE HealthCare submits periodic and current reports that offer detail on its financial condition, governance, and significant corporate events.
Among the key documents investors often review are Form 10-K annual reports and Form 10-Q quarterly reports, which contain information on the company’s operations across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses. In addition, Form 8-K current reports disclose material events. Recent 8-K filings have described items such as a three-year senior unsecured term loan credit facility, the issuance of senior notes due 2028 and 2035, the intended use of proceeds in connection with an announced acquisition of Intelerad Medical Systems, quarterly financial results, and changes to the board of directors.
Investors interested in GEHC can also use this page to track other filing types, such as registration statements and, when applicable, proxy materials related to governance matters. These documents help explain the company’s capital structure, including senior notes and credit facilities, and outline covenants, events of default, and other terms referenced in the filings.
Stock Titan enhances access to GE HealthCare’s filings by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight key points in lengthy documents. This can help users quickly understand the implications of new 10-K, 10-Q, and 8-K filings, as well as monitor developments related to financing arrangements, acquisitions, and other significant events disclosed by GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc Schedule 13G/A amendment shows The Vanguard Group reporting 0 shares and 0% beneficial ownership of Common Stock as of the amendment. The filing notes an internal realignment on 01/12/2026 that led to disaggregated reporting by Vanguard subsidiaries.
GE HealthCare Technologies Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 7, 2026. Holders of 456,290,143 common shares as of March 9, 2026 can vote on three items: electing eight directors for one-year terms, an advisory say‑on‑pay vote on 2025 executive compensation, and ratifying Deloitte & Touche LLP as independent auditor for 2026.
The company highlights 2025 revenue of $20.6 billion, record backlog, and earnings per share growth driven by volume and productivity despite tariff impacts. The board emphasizes strong governance, with seven of eight nominees independent, majority voting, proxy access, no poison pill or dual‑class shares, and a 15‑year director term limit. Executive pay is positioned as performance‑based and long‑term, with rigorous stock ownership requirements, a broad clawback policy, and prohibitions on hedging and pledging.
Lobo Kevin reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director Kevin Lobo received an equity award of 777 restricted stock units of common stock. These RSUs were granted at no cash cost to him and represent compensation rather than an open-market purchase or sale.
According to the award terms, 100% of the 777 restricted stock units will vest on the earlier of GE HealthCare’s next annual meeting of stockholders or March 13, 2027. Each vested unit entitles him to receive one share of GE HealthCare common stock, and settlement may be deferred under the company’s non-employee director compensation plan.
GE HealthCare Technologies Inc. director Kevin Lobo filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. This filing establishes his reporting status as a director but does not report any insider stock transactions or positions in this excerpt.
GE HealthCare Technologies Inc. reported that its Board appointed Kevin A. Lobo, Chair and CEO of Stryker Corporation, as a director effective March 13, 2026, and named him to the Talent, Culture, and Compensation Committee. His term runs until the 2026 Annual Meeting and he will be compensated under the company’s standard non-employee director program, with an indemnification agreement matching the form used for other directors.
The company also disclosed that directors Risa Lavizzo-Mourey and Tomislav Mihaljevic will not stand for re-election at the 2026 Annual Meeting due to other commitments, and their decisions do not reflect any disagreement with the company. A press release announcing Mr. Lobo’s appointment was issued on March 17, 2026 and furnished as an exhibit.
Bankes Jeannette reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. reported that Jeannette Bankes, CEO of Patient Care Solutions, received new equity awards. On March 2, 2026, she was granted an employee stock option for 18,038 shares of common stock and 6,861 restricted stock units, both at no cash cost.
The restricted stock units each represent one share of GE HealthCare common stock and are scheduled to vest 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock option becomes exercisable on the same 33/33/34 schedule. Following these awards, she directly holds 43,892 shares of common stock and 18,038 options.
GE HealthCare Technologies Inc. reported that its General Counsel and Corporate Secretary, Frank R. Jimenez, received new equity awards. He was granted an employee stock option covering 28,697 shares of common stock at an exercise price of $0.00 per share, and a separate award of 10,915 shares of common stock, reported as a grant or award acquisition.
The common stock award represents restricted stock units, each equal to one share of GE HealthCare common stock. For that award, 33% will vest on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock option vests on the same schedule, with 33% becoming exercisable on each of those first two dates and 34% on the third. After these transactions, Jimenez directly holds 28,697 employee stock options and 92,182 shares of common stock.
Kass-Hout Taha reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. reported that Chief Technology Officer Taha Kass-Hout received equity awards on March 2, 2026. He was granted an employee stock option for 34,847 shares and 13,254 shares of common stock as a restricted stock unit award, vesting in stages from September 2, 2027 through September 2, 2029.
GE HealthCare Technologies Inc. Chief People Officer Adam Y. Holton reported awards of company equity on March 2, 2026. He received an employee stock option for 14,348 shares of common stock at an exercise price of $0.00 per share, bringing his directly held options to 14,348.
On the same date, he was granted 5,457 shares of common stock, increasing his directly held common shares to 22,225. The common stock award consists of restricted stock units, with 33% vesting on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock options follow the same 33%/33%/34% vesting and exercisability schedule on those dates.